Multiple Therapies,
One Virus.
KALIVIR is developing cutting-edge, next-generation
oncolytic viral immunotherapy programs for treatment
of cancer. We design safe and potent oncolytic
product candidates to treat patients across mulltiple
tumor types. Learn more about us
PRESENTATIONS – Novel Vaccinia Enhanced Template (VET) Oncolytic Platform
NEWS AND EVENTS READ MORE May –23, 2022 – KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses here. READ MORE